Yoshihiro Inamoto, Mary E. D

Slides:

Advertisements

Similar presentations

Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.

Advertisements

Center for International Blood and Marrow Transplant Research Chronic Graft-versus- Host Disease Risk Score Predicts Mortality in an Independent Validation.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic.

Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant.

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation Mats Remberger, Emma.

HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced- Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from.

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia Hien Duong Liu, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani,

Marcelo C. Pasquini, Mei-Jie Zhang, Bruno C

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer Brigitta Omazic, Mats Remberger, Lisbeth Barkholt, Gunnar.

Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.

Outcomes of Hematopoietic Cell Transplantation in Adult Patients with Acquired Aplastic Anemia Using Intermediate-Dose Alemtuzumab-Based Conditioning

Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease Areej El-Jawahri, Joseph Pidala,

Danielle M. Zerr, Michael Boeckh, Colleen Delaney, Paul J

Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life

Re: Twenty-Year Follow-Up in Patients with Aplastic Anemia Given Marrow Grafts from HLA-Identical Siblings and Randomized to Receive Methotrexate/Cyclosporine.

Clinical Benefit of Response in Chronic Graft-versus-Host Disease

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease Paul J. Martin, Barry.

Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants Stella M. Davies, Dan.

Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigen–Identical Sibling Transplantations for Chronic Lymphocytic.

A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing.

Should Methotrexate plus Calcineurin Inhibitors Be Considered Standard of Care for Prophylaxis of acute Graft-versus-Host Disease? Rainer Storb, Joseph.

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma George.

Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia Daniella.

Kasiani C. Myers, Stella M. Davies

Betty K. Hamilton, Lisa Rybicki, Sally Arai, Mukta Arora, Corey S

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation.

A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning.

Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease.

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Hematopoietic Cell Transplantation for Children with Acute Lymphoblastic Leukemia in Second Complete Remission: Similar Outcomes in Recipients of Unrelated.

Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation Alison W. Loren,

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Comparison of Outcomes after Transplantation of G-CSF–Stimulated Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-Matched Sibling.

Analysis of Gastrointestinal and Hepatic Chronic Grant-versus-Host Disease Manifestations on Major Outcomes: A Chronic Grant-versus-Host Disease Consortium.

Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin–Conditioned Hematopoietic Cell Transplantation Amit Kalra,

Akiko M. Saito, Corey Cutler, David Zahrieh, Robert J

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts Boglarka.

Outcomes of Human Leukocyte Antigen–Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-

Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen H.

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Risk Factors Affecting Outcome of Second HLA-Matched Sibling Donor Transplantations for Graft Failure in Severe Acquired Aplastic Anemia John T. Horan,

Aplastic Anemia: Pathophysiology and Treatment

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category Ann Woolfrey, Stephanie J.

Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients.

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality Margaret.

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation Philippe Armand, Haesook.

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic.

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation:

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

One-Antigen Mismatched Related versus HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Adults with Acute Leukemia: Center for International.

Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning.

Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes.

Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts Yi-Bin Chen, Julie Aldridge,

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human.

Mary Eapen Biology of Blood and Marrow Transplantation

Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord.

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Presentation transcript:

Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia Yoshihiro Inamoto, Mary E.D. Flowers, Tao Wang, Alvaro Urbano-Ispizua, Michael T. Hemmer, Corey S. Cutler, Daniel R. Couriel, Amin M. Alousi, Joseph H. Antin, Robert Peter Gale, Vikas Gupta, Betty K. Hamilton, Mohamed A. Kharfan-Dabaja, David I. Marks, Olle T.H. Ringdén, Gérard Socié, Melhem M. Solh, Görgün Akpek, Mitchell S. Cairo, Nelson J. Chao, Robert J. Hayashi, Taiga Nishihori, Ran Reshef, Ayman Saad, Ami Shah, Takanori Teshima, Martin S. Tallman, Baldeep Wirk, Stephen R. Spellman, Mukta Arora, Paul J. Martin Biology of Blood and Marrow Transplantation Volume 21, Issue 10, Pages 1776-1782 (October 2015) DOI: 10.1016/j.bbmt.2015.05.023 Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Comparison of outcomes with TAC+MTX versus CSP+MTX. Hazard ratios with 95% confidence intervals are shown for TAC+MTX compared with CSP+MTX. (A) Transplantation from an HLA-identical sibling (SIB). (B) Transplantation from an unrelated donor (URD). ∗All models were adjusted for graft type, year of transplantation, and center effect. For grades II to IV GVHD in URD, results were adjusted for ABO matching, cytomegalovirus serology, HLA matching, pretransplantation therapy, and donor-recipient gender combination. For grades III to IV GVHD in SIB, results were adjusted for ABO matching. For grades III to IV GVHD in URD, results were adjusted for donor age. For chronic GVHD in SIB, results were adjusted for patient age. For chronic GVHD in URD, results were adjusted for patient age, HLA matching, time from SAA diagnosis to transplantation, pretransplantation therapy, and total body irradiation dose in conditioning regimen. For mortality in SIB, results were adjusted for patient age, type of ATG or alemtuzumab in the conditioning regimen, or GVHD prophylaxis and cytomegalovirus serology. For mortality in URD, results were adjusted for patient age, performance score at transplantation, and HLA matching. For ANC recovery in SIB, results were adjusted for patient age and use of growth factors after transplantation. For ANC recovery in URD, results were adjusted for donor-recipient gender combination and use of growth factors after transplantation. For platelet recovery in SIB, results were adjusted for ABO matching, patient age, type of ATG or alemtuzumab in the conditioning regimen or GVHD prophylaxis, cytomegalovirus serology, time from SAA diagnosis to transplantation, and performance score at transplantation. For platelet recovery in URD, results were adjusted for performance score at transplantation. Biology of Blood and Marrow Transplantation 2015 21, 1776-1782DOI: (10.1016/j.bbmt.2015.05.023) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Comparison of outcomes with TAC+MTX versus CSP+MTX, stratified by donor and graft type. Hazard ratios with 95% confidence intervals are shown for TAC+MTX compared with CSP+MTX. (A) Transplantation from an HLA-identical sibling. (B) Transplantation from an unrelated donor. Some results for PBSCT were not available because of small numbers of events (grades III to IV acute GVHD and secondary graft failure in SIB; and grades III to IV acute GVHD in URD). ∗All models were adjusted for year of transplantation and center effect. For grades II to IV GVHD in URD, results were adjusted for ABO matching, cytomegalovirus serology, HLA matching, pretransplantation therapy, and donor-recipient gender combination. For grades III to IV GVHD in SIB, results were adjusted for ABO matching. For grades III to IV GVHD in URD, results were adjusted for donor age. For chronic GVHD in SIB, results were adjusted for patient age. For chronic GVHD in URD, results were adjusted for patient age, HLA matching, time from SAA diagnosis to transplantation, pretransplantation therapy, and total body irradiation dose in conditioning regimen. For mortality in SIB, results were adjusted for patient age, type of ATG or alemtuzumab in the conditioning regimen or GVHD prophylaxis, and cytomegalovirus serology. For mortality in URD, results were adjusted for patient age, performance score at transplantation and HLA matching. For ANC recovery in SIB, results were adjusted for patient age and use of growth factors after transplantation. For ANC recovery in URD, results were adjusted for donor-recipient gender combination and use of growth factors after transplantation. For platelet recovery in SIB, results were adjusted for ABO matching, patient age, type of ATG or alemtuzumab in the conditioning regimen or GVHD prophylaxis, cytomegalovirus serology, time from SAA diagnosis to transplantation, and performance score at transplantation. For platelet recovery in URD, results were adjusted for performance score at transplantation. Biology of Blood and Marrow Transplantation 2015 21, 1776-1782DOI: (10.1016/j.bbmt.2015.05.023) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions